J Drugs Dermatol. 2023 Jun 1;22(6):582-587. doi: 10.36849/JDD.7587.
Acne vulgaris is the most common skin condition in the US, affecting up to 50 million Americans. The American Academy of Dermatology (AAD) guidelines on acne treatment were developed to provide recommendations for the diagnosis, grading, and treatment of acne in adolescents and adults to support clinicians in their therapeutic decision-making process. The most recent acne guidelines were published in 2016, and the approach to care and the therapeutic landscape of acne have evolved since that time. The Acne Management Consensus Roundtable was convened in 2022 to discuss unmet needs in the management of acne. The main focus of the meeting was the role of androgens in acne pathology; the evaluation of clascoterone, the first topical anti-androgen that specifically addresses sebum production in acne; and the identification of the place of clascoterone in therapy. Clascoterone was approved by the US Food and Drug Administration for the treatment of acne in patients 12 years and older in 2020. This report aims to highlight important limitations of the 2016 AAD treatment guidelines and to familiarize practitioners with clascoterone and its indication, efficacy and safety profile, and potential use across diverse patient populations. With its new mechanism of action, clascoterone may be able to fulfill important unmet needs in acne treatment. Baldwin H, Farberg AS, Frey C, et al. Unmet needs in the management of acne vulgaris: a consensus statement. J Drugs Dermatol. 2023;22(6):582-587. doi:10.36849/JDD.7587.
寻常痤疮是美国最常见的皮肤疾病，影响多达 5000 万美国人。美国皮肤病学会 (AAD) 的痤疮治疗指南旨在为青少年和成年人的痤疮诊断、分级和治疗提供建议，以支持临床医生的治疗决策过程。最新的痤疮指南于 2016 年发布，自那时以来，治疗方法和痤疮的治疗领域已经发生了变化。2022 年召开了痤疮管理共识圆桌会议，讨论痤疮管理中未满足的需求。会议的主要重点是雄激素在痤疮发病机制中的作用；评估氯司特龙，这是第一种专门针对痤疮皮脂生成的局部抗雄激素；并确定氯司特龙在治疗中的地位。氯司特龙于 2020 年获得美国食品和药物管理局批准，用于治疗 12 岁及以上患者的痤疮。本报告旨在强调 2016 年 AAD 治疗指南的重要局限性，并使从业者熟悉氯司特龙及其适应症、疗效和安全性概况，以及在不同患者群体中的潜在用途。氯司特龙具有新的作用机制，可能能够满足痤疮治疗中未满足的重要需求。Baldwin H, Farberg AS, Frey C, et al. Unmet needs in the management of acne vulgaris: a consensus statement. J Drugs Dermatol. 2023;22(6):582-587. doi:10.36849/JDD.7587.
